EMA approves multiple new treatments across cancer, cardiovascular, ophthalmology, and dermatology while research challenges conventional diabetes prevention wisdom and explores AI and natural supplement benefits.

The European Medicines Agency has backed expanded uses for multiple cancer drugs, moving toward biomarker-driven treatment approaches and earlier-line therapeutic interventions.

A long-term follow-up study challenges prediabetes management dogma, finding that weight loss alone may not prevent type 2 diabetes development in some older adults, suggesting more nuanced patient stratification is needed.

EMA advisers approved a botulinum toxin treatment for moderate to severe frown lines with rapid onset (8 hours) and effects lasting 2-3 weeks, expanding aesthetic medicine options in Europe.

The EMA recommended marketing authorization for a hybrid colchicine medicine designed for secondary prevention of atherothrombotic events in adults with stable coronary disease, addressing cardiovascular risk reduction.

A new anti-VEGF biosimilar has moved closer to European approval for treating multiple vision-threatening retinal diseases including choroidal neovascularization, potentially improving access to retinal disease treatment.

Research demonstrates that artificial intelligence decision support tools show promise in emergency department settings, though implementation approaches are critical for ensuring patient safety and clinical benefit.

Curcumin supplementation from turmeric was found to produce clinically meaningful reductions in depressive symptoms in new research, suggesting potential for natural compounds in mental health management.

The history of cataract surgery reveals surprising developments from ancient medical practices through modern techniques, highlighting the evolution of one of medicine's most routine yet impactful procedures.